Objective To explore the safety, feasibility and effectiveness of autologous umbilical cord blood (UCB) therapy combined with rehabilitation on children with brain injury, in order to provide a new idea and approach for the treatment of children with brain injury in clinic. Methods A total of 11 children with brain injury who underwent autologous UCB infusion treatment and adhered to rehabilitation in Shenzhen Children′s Hospital from July 2018 to May 2020 were selectedinto observation group, and 11 brain injury children with no significant difference in functional status from observation group were selected as control group. The observation group received rehabilitation treatment for half a year since UCB infusion, while the control group only received conventional rehabilitation treatment for half a year. Both groups were evaluated for their functional level before and half a year after treatment. Paired-sample t-test was used to compare the levels of neurone specific enolase (NSE) and inflammatory factors before treatment and 2 weeks after UCB therapy. Results The gross and fine motor skill, rough intelligence scores of the observation and the control group significantly improved after treatment in both observation group and control group. Besides, the above index scores were significantly higher in observation group (t=7.214, 3.310, 3.641, P<0.05). Two weeks after treatment, the pro-inflammatory cytokines(IL-2, IL-6) and NSE levels of the children in observation group were significantly decreased(t=3.304, 3.206, 3.709, P<0.05), while the anti-inflammatory cytokines(IL-4, IL-10) level was significantly increased(t=3.937, 4.316, P<0.05). In addition, no obvious side effects and complications were found during the treatment and long-term follow-up. Conclusion Autologous UCB infusion is a safe and feasible method, and has a significant effect in improving the functional level of children with brain injury when combined with rehabilitation training.
Key words
autologous cord blood /
brain injury /
rehabilitation /
efficacy
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] He C, Liu L, Chu Y, et al. National and subnational all-cause and cause-specific child mortality in China, 1996-2015: A systematic analysis with implications for the sustainable development goals[J]. Lancet Glob Health, 2017, 5(2): e186-e197.
[2] Norman M, Hallberg B, Abrahamsson T, et al. Association between year of birth and 1-year survival among extremely preterm infants in sweden during 2004-2007 and 2014-2016[J]. JAMA, 2019, 321(12): 1188-1199.
[3] Peng X, Song J, Li B, et al. Umbilical cord blood stem cell therapy in premature brain injury: Opportunities and challenges[J]. J Neurosci Res, 2020 , 98(5): 815-825.
[4] Zhang J, Yang C, Chen J, et al. Umbilical cord mesenchymal stem cells and umbilical cord blood mononuclear cells improve neonatal rat memory after hypoxia-ischemia[J]. Behav Brain Res, 2019, 362: 56-63.
[5] Jiao Y, Li XY, Liu J. A new approach to cerebral palsy treatment: Discussion of the effective components of umbilical cord blood and its mechanisms of action[J]. Cell Transplant, 2019, 28(5): 497-509.
[6] 张怡文, 曹建国, 郭津, 等. 网状密集式悬吊训练对发育迟缓儿童粗大运动功能的疗效分析[J]. 中国儿童保健杂志, 2019, 27(4): 457-460.
[7] McDonald CA, Penny TR, Paton MCB, et al. Effects of umbilical cord blood cells, and subtypes, to reduce neuroinflammation following perinatal hypoxic-ischemic brain injury[J]. J Neuroinflammation, 2018, 15(1): 47.
[8] Sun JM, Kurtzberg J. Cord blood for brain injury[J]. Cytotherapy, 2015, 17(6): 775-785.
[9] McDonald CA, Fahey MC, Jenkin G, et al. Umbilical cord blood cells for treatment of cerebral palsy: timing and treatment options[J]. Pediatr Res, 2018, 83(1-2): 333-344.
[10] Boruczkowski D, Pujal JM, Zdolińska-Malinowska I. Autologous cord blood in children with cerebral palsy: A review[J]. Int J Mol Sci, 2019, 20(10): 2433.
[11] Yu Y, Yan Y, Luo Z, et al. Effects of human umbilical cord blood CD34(+) cell transplantation in neonatal hypoxic-ischemia rat model[J]. Brain Dev, 2019, 41(2): 173-181.
[12] Sun JM, Kurtzberg J. Cord blood for brain injury[J]. Cytotherapy, 2015, 17(6): 775-785.
[13] Hossein A, Farzaneh G,Mehdi D, et al. Human umbilical cord mesenchymal stem cell-derived extracellular vesicles: A novel therapeutic paradigm[J]. J Cell Physiol, 2020, 235(2): 706-717.
[14] Qin X, Qiao H, Wu S, et al. Curcumin inhibits monocyte chemoattractant protein-1 expression in TNF-alpha induced astrocytes through AMPK pathway[J].Neurochem Res, 2018, 43(4): 775-784
[15] Drommelschmidt K, Serdar M, Bendix I, et al. Mesenchymal stem cell-derived extracellular vesicles ameliorate inflammation-induced preterm brain injury[J]. Brain Behav Immun, 2017, 60: 220-232.
[16] Sanberg PR, Ehrhart J. A hallmark clinical study of cord blood therapy in adults with ischemic stroke[J]. Cell Transplant, 2019, 28(9-10): 1329-1332.
[17] Liska MG, Dela Peña I. Granulocyte-colony stimulating factor and umbilical cord blood cell transplantation: Synergistic therapies for the treatment of traumatic brain injury[J]. Brain Circ, 2017, 3(3): 143-151.
PDF(534 KB)
